OCUMETICS TECHNOLOGY CORP Aktie

Calgary, Alberta – TheNewswire - June 26, 2025 - Ocumetics Technology Corp . (“Ocumetics” or the “Company”) (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO), a leader in advanced ophthalmic technology, is pleased to announce the successful completion of a virtual site initiation visit at its clinical partner site in Mexico City. This critical milestone confirms that the investigative site is fully prepared to conduct the upcoming first-in-human (FIH) clinical study of its revolutionary accommodating intraocular lens (the “Ocumetics Lens”), in accordance with international standards. Dean Burns, CEO of Ocumetics commented on the significance of the site inspection: “Conducting the clinical partner site initiation is a major step forward in bringing the Ocumetics Lens to clinical reality. The site initiation occurred remotely and will be finalized when our team visits the site. Successful completion of this critical process confirms clinical readiness to commence the study and to perform surgeries on our first patients. We couldn't be more excited to proceed to validate the clinical environment for what will be a landmark moment in Ocumetics' history.”» Mehr auf thenewswire.com

Calgary, Alberta – TheNewswire - June 24, 2025 - Ocumetics Technology Corp . (“Ocumetics” or the “Company”) (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO), a leader in advanced ophthalmic technology, is pleased to confirm the culmination of nearly two decades of research and development as it prepares for first-in-human (FIH) clinical studies of its revolutionary accommodating intraocular lens (the “Ocumetics Lens”). “This moment is nothing short of transformational,” said Dean Burns, CEO of Ocumetics.  “With clinical study site initiation set to begin this week, we are now taking the most significant step yet in bringing the Ocumetics Lens to market.  What began as a dream to restore the youthful eye's natural ability to focus distant and near objects after cataract surgery is one step closer to becoming a reality.  With a world class team, innovative technology, and unwavering determination, we are redefining what's possible in ophthalmology.”» Mehr auf thenewswire.com

Calgary, Alberta – TheNewswire - June 4, 2025 - Ocumetics Technology Corp. (“ Ocumetics ” or the “ Corporation ”) (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO) announces that it proposes to complete a private placement (the “ Offering ”) of up to 6,000,000 units of the Corporation (“ Units ”) at a price of $0.35 per Unit for gross proceeds of up to $2,100,000. There will be no minimum subscription level for the Offering.  Each Unit will consist of one common share in the share capital of the Corporation (“ Common Share ”) and one-half of one common share purchase warrant. Each whole warrant (“ Warrant ”) will entitle the holder to purchase one additional Common Share at an exercise price of $0.50 for a period of 24 months from the date of issuance of the Warrant.   The Warrants will be subject to an acceleration clause such that if the volume weighted average trading price of the Common Shares on the TSX Venture Exchange is at ‎‎least $0.60 per Common Share for a period of 30 consecutive trading days, the expiry date of the Warrants may be ‎accelerated by the Corporation to a date that is not less than 30 days after the date that ‎notice of such acceleration is provided to the Warrant holders by way of a press release.» Mehr auf thenewswire.com